Torys LLP acted for Entos Pharmaceuticals. On January 6, 2022, Eli Lilly and Company (NYSE:LLY) acquired exclusive rights to Entos’ Fusogenix nucleic acid delivery technology to research,...
Eli Lilly and Company and Entos Pharmaceuticals, Inc.’s Research and Collaboration Agreement
Entos Pharmaceuticals’ Agreement with BioMarin Pharmaceutical
Torys LLP acted for Entos Pharmaceuticals on the deal. Entos Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. entered into an agreement that will see Entos apply its Fusogenix nucleic...